Ressources - Page 20 sur 43 - Oncodesign Services

Home . [FR] Le Bien Public – Mouvements de fond, Oncodesign augmente son capital

02/03/2019

[EN] Life Science – Hybrid business model guarantees substainable and healthy growth

Lire

01/03/2019

[FR] Hybrid business model guarantees substainable and healthy growth

Webinaire

21/02/2019

[EN] Supporting your immuno-onco drug discovery programs from hit identification to candidate selection!

Immunotherapies in Oncology : a key for drug discovery programs performing relevant and robust assays to predict therapeutic efficiencies

11/02/2019

[FR] Biotechs: 3 paris à tenter sans tarder

Actualités

11/02/2019

[FR] Oncodesign: Année charnière avant un nouveau cycle

11/02/2019

[FR] Biotech Finances – Oncodesign: Année charnière avant un nouveau cycle

Poster

07/02/2019

AACR Atlanta – Customized methodology to investigate immuno-oncology drugs using humanized mouse models

Poster

07/02/2019

AACR Atlanta – Targeted external or internal radiotherapy in combination with immunotherapies and companion imaging diagnostics

Poster

07/02/2019

AACR Atlanta – Induction of immunogenic cell death and enhancement of dendritic cell function

Poster

07/02/2019

AACR Atlanta – Immune Checkpoint Blockade and Autoimmune Diseases

Poster

07/02/2019

Immuno-Oncology Summit Europe – Development of Pre-Clinical Assays to Support Drug Discovery Programs in Immuno-Oncology

05/02/2019

[FR] Oncodesign amène un « derisking » important et cela est de plus en plus perçu par les investissseurs

1 2 … 19 20 21 … 42 43

Contactez-nous

20 rue Jean Mazen - FR - 21000 Dijon
Tél.+33 380 788 260

Je prends contact

La science vient à vous

Recevez nos informations générales !